Paula Z. Prosek
Clinical Research Scientist & Laboratory Manager, Clinical Genomics, Translational Research The Royal Marsden, NHS, UK
Seminars
Wednesday 4th February 2026
A Multicenter European Laboratory Evaluation of a Rapid End-to-End Liquid Biopsy NGS Solution for Genomic Testing in Advanced NSCLC
3:45 pm
- Timely and comprehensive molecular profiling is essential for guiding treatment decisions in advanced non–small cell lung cancer (NSCLC). Liquid biopsy–based NGS approaches offer a minimally invasive means to support biomarker testing, particularly where tissue is limited or unavailable
- End-to-end liquid biopsy NGS solutions designed for decentralized implementation may help expand access to molecular testing by enabling use in smaller laboratories equipped with low- to medium-throughput sequencing platforms, while supporting clinically relevant turnaround times
- Current kitted liquid biopsy assays generally fall into amplicon-based targeted panels or hybrid capture–based comprehensive genomic profiling approaches, each associated with distinct workflow requirements, sequencing demands, and genomic coverege
- In this multicenter European evaluation, we present a rapid, targeted liquid biopsy NGS solution for advanced NSCLC. We assess workflow feasibility, sequencing requirements, and turnaround time, and discuss the potential role of such approaches in supporting decentralized molecular testing for lung cancer patients
